Hastings Julie M, Licence Diana R, Burton Graham J, Charnock-Jones D Stephen, Smith Stephen K
Reproductive Molecular Research Group, Department of Pathology, University of Cambridge, Cambridge, United Kingdom CB2 1QP.
Endocrinology. 2003 Jan;144(1):326-34. doi: 10.1210/en.2002-220641.
The uterine response to 17beta-estradiol (E2) includes increased water retention, enhanced vascular permeability, DNA and RNA synthesis, and increased cellular mitosis. We have used the natural antagonist of vascular endothelial growth factor A (VEGF-A), sflt-1 (soluble form of flt-1), to determine whether the edematous and proliferative effects of E2 in the uterus are mediated by VEGF-A. Female BALB/c mice were ovariectomized and treated with E2 (10 micro g/kg) in the absence or presence of sflt-1 (0.8 and 4.0 mg/kg) for 24 h. E2 induced increases in uterine mass from 25.3 to 36.8 mg, in total cross-sectional uterine area from 771 to 1133 micro m(2), in cross-sectional endometrial area from 268 to 569 micro m(2), and in the mitotic index of lumenal epithelial cells from 0% to 53%. Antagonism with sflt-1 reduced the E2-induced increases in total uterine area to 779 micro m(2), endometrial area to 398 micro m(2) and the mitotic index of lumenal epithelial cells to 25%, but the E2-induced increase in uterine mass was not significantly reduced. From these data we conclude that the edematous response and proliferation of lumenal epithelial cells in the murine uterus are mediated in part through VEGF-A. These data suggest that sflt-1 could be a useful anti-VEGF-A agent and may be effective in modifying uterine biology.
子宫对17β-雌二醇(E2)的反应包括水分潴留增加、血管通透性增强、DNA和RNA合成以及细胞有丝分裂增加。我们使用血管内皮生长因子A(VEGF-A)的天然拮抗剂sflt-1(可溶性fms样酪氨酸激酶-1)来确定E2在子宫中的水肿和增殖作用是否由VEGF-A介导。对雌性BALB/c小鼠进行卵巢切除,并在不存在或存在sflt-1(0.8和4.0 mg/kg)的情况下用E2(10μg/kg)处理24小时。E2导致子宫重量从25.3毫克增加到36.8毫克,子宫总横截面积从771平方微米增加到1133平方微米,子宫内膜横截面积从268平方微米增加到569平方微米,管腔上皮细胞的有丝分裂指数从0%增加到53%。用sflt-1拮抗可将E2诱导的子宫总面积增加降低至779平方微米,子宫内膜面积降低至398平方微米,管腔上皮细胞的有丝分裂指数降低至25%,但E2诱导的子宫重量增加没有显著降低。根据这些数据,我们得出结论,小鼠子宫中管腔上皮细胞的水肿反应和增殖部分是通过VEGF-A介导的。这些数据表明,sflt-1可能是一种有用的抗VEGF-A药物,可能对改变子宫生物学特性有效。